Clinical trialNCT03710876CompletedPhase 3Interventional

Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma

SponsorFerring Ventures LimitedEnrollment53Malignant Pleural Mesothelioma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study will evaluate intrapleural administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in combination with Celecoxib and Gemcitabine in patients with histologically confirmed Malignant Pleural Mesothelioma (MPM) who have failed a minimum of 1 treatment regimen and a maximum of 2 treatment regimens, 1 of which must have been an anti-folate and platinum combination regimen. Eligible patients will be randomized 1:1 to either: 1. Treatment group: rAd-IFN + Celecoxib followed by Gemcitabine 2. Control group: Celecoxib followed by Gemcitabine Patients randomized to the treatment group will receive rAd-IFN administered into the pleural space via an Intrapleural catheter (IPC) or similar intrapleural device on study Day 1. The primary objective of this study is to compare the overall survival (OS) associated with rAd IFN, when administered with celecoxib and gemcitabine, versus that associated with celecoxib and gemcitabine alone for the treatment of patients with MPM

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Daniel Sterman, MD
NYU Langone Laura and Isaac Perlmutter Cancer Center
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

29 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia
Monash Medical Centre
Clayton, Victoria, Australia

Canada

Institut Universitaire de Cardiologie Et de Pneumologie de Quebec
Québec, Sainte-Foy, Canada

France

Institut Bergonie
Bordeaux, France
Chru de Brest - Hopital Augustin Morvan
Brest, France
Chu de Caen - Hopital Cote de Nacre
Caen, France
Chru de Lille
Lille, France
Institut Curie - Oncologie Medicale
Paris, France
Centre Hospitalier Lyon Sud
Pierre-Bénite, France
Chu de Nantes - Hôpital Nord Laennec
Saint-Herblain, France

Germany

Evangelisches Krankenhaus Hamm
Hamm, Germany
Universitatsklinikum Regensburg
Regensburg, Germany

Italy

Azienda Ospedaliero Universitaria Senese, Cancer Immunotherapy
Siena, Tuscany, Italy

Poland

Med Polonia Sp. Z O.O.
Poznan, Poland
Centrum Onkologii Instytut Im. Marii Sklodowskiej - Curie, Klinika Nowotworow Tkanek Miekkich, Kosci I Czerniakow
Warsaw, Poland

Russia

Petrov National Medical Research Center of Oncology
Saint Petersburg, Russia
Volgograd Regional Clinical Oncology Dispensary
Volgograd, Russia

United Kingdom

Derriford Hospital ; Derriford Hospital
Plymouth, Devon, United Kingdom
Churchill Hospital
Oxford, Oxford, United Kingdom
Beatson, West of Scotland Cancer Centre
Glasgow, Scotland, United Kingdom
Royal Marsden Foundation Trust
Sutton, Surrey, United Kingdom
Guy'S and St. Thomas' Nhs Trust
London, United Kingdom

United States

University of California, Los Angeles (ucla) - Medical Center
Los Angeles, California, United States
University of California, San Francisco (ucsf)
San Francisco, California, United States
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, United States
Marlene & Stewart Greenbaum Comprehensive Cancer Center
Baltimore, Maryland, United States
University of Maryland Medical Center
Baltimore, Maryland, United States
Masonic Cancer Center - University of Minnesota
Minneapolis, Minnesota, United States
University of Pennsylvania Abramson Cancer Center
Philadelphia, Pennsylvania, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Celecoxib →Gemcitabine →Nadofaragene firadenovec

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 21 Jan 2019
Primary completion: 29 Mar 2024
Completion: 16 Jan 2026
Last update posted: 21 Apr 2026
Registered enrollment: 53
Registry id: NCT03710876

Cross-registrations

EU-CTR / CTIS (EudraCT)2017-003169-82

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.